2019 CSCO:国内白血病·淋巴瘤专场:聚焦淋巴瘤治疗前沿,BTK抑制剂在B细胞淋巴瘤中应用前景广阔

2019-10-03 佚名 肿瘤资讯

第22届全国临床肿瘤学会(CSCO)年会在厦门市隆重举行。作为中国肿瘤学领域的顶级学术盛宴,本届CSCO可谓汇聚了众多国内肿瘤学专家和学者,探讨了各类肿瘤的诊疗进展。「国内白血病·淋巴瘤专场」作为血液肿瘤的分会场之一也聚集诸位血液肿瘤领域大咖,分享了诸多精彩内容。特将该专场的主要内容概括如下,以供参考。

第22届全国临床肿瘤学会(CSCO)年会在厦门市隆重举行。作为中国肿瘤学领域的顶级学术盛宴,本届CSCO可谓汇聚了众多国内肿瘤学专家和学者,探讨了各类肿瘤的诊疗进展。「国内白血病·淋巴瘤专场」作为血液肿瘤的分会场之一也聚集诸位血液肿瘤领域大咖,分享了诸多精彩内容。特将该专场的主要内容概括如下,以供参考。

Session one—— PTCL诊疗进展、PD-1/PD-L1抑制剂在淋巴瘤中的应用及论文交流

Session one版块是由北京大学肿瘤医院的朱军教授、中山大学附属肿瘤医院的吕跃教授主持。第一位讲者为复旦大学附属肿瘤医院的曹军宁教授,其讲题为“PTCL的治疗策略”。曹教授指出,外周T细胞淋巴瘤(PTCL)是一类分类及发病机制极为复杂的T细胞淋巴瘤,在诊断上存在一定的难度,病理标本应首选组织活检,而非穿刺标本。在治疗方面,CD30单抗Brentuximab Vedotin(BV)联合CHP方案推荐作为CD30阳性的PTCL患者的一线方案。而对于CD30阴性的PTCL患者而言,传统的化疗方案(CHOP或CHOP样方案)应作为推荐的治疗。

天津医科大学肿瘤医院的张会来教授围绕“PD-1/PD-L1单克隆抗体在恶性淋巴瘤的研究方向和热点问题”这一内容进行了精彩解读。张教授首先介绍了PD-1/PD-L1抑制剂的作用机制,强调了其在霍奇金淋巴瘤(cHL)中表现出显着的疗效并已获批。近年来,尽管PD-1/PD-L1抑制剂在B细胞非霍奇金淋巴瘤(NHL)领域中的疗效进展并不明显,但也有一些研究方向及热点——转向特定亚型的NHL治疗(原发睾丸、纵膈或中枢神经系统的B细胞淋巴瘤等)。此外,张教授针对PD-1/PD-L1抑制剂治疗的生物学标记物(如9p24.1基因扩增、干扰素表达及肠道微生物菌群等)研究进展作为详细的介绍和分析。

在论文交流环节,北京大学肿瘤医院刘卫平教授、陆军军医大学新桥医院的刘耀教授分别分享论文。刘卫平教授的论文题目分别为“Burden of lymphoma in China, 2006-16:an anlysis of Global Burden of Disease Study 2016”,全面分析了我国现阶段淋巴瘤的流行病学及疾病负担情况。刘耀教授则围绕“西南地区双次自体造血干细胞移植治疗成人T淋巴母细胞的多中心研究”这一讲题阐述了二次自体干细胞移植对于成人T淋巴母细胞瘤的重要价值。

Session two——BTK抑制剂在B细胞淋巴瘤中前景广阔、无化疗时代下FL治疗

Session two版块是由北京大学医学部高子芬教授、中国医学科学院血液病医院肖志坚教授联袂主持。第一位讲者是来自哈尔滨血液病肿瘤研究所的赵东陆教授,赵教授围绕“BTK抑制剂在B细胞淋巴瘤中的应用进展”展开了全面的解析。在作用机制方面,BTK抑制剂主要通过三大途径达到抑制肿瘤B细胞的效应:促进凋亡并抑制肿瘤细胞增殖、减少肿瘤B细胞粘附、抑制趋化因子和阻止B细胞迁移。靶向BTK已然成为B细胞淋巴瘤治疗的重要策略之一。

中山大学附属肿瘤医院的李志铭教授的讲题为“无化疗时代下滤泡性淋巴瘤(FL)的治疗”。李教授指出,随着淋巴瘤新药的不断涌现,诸如BTK抑制剂伊布替尼等药物在FL等淋巴瘤中取得了显着疗效。这使得无化疗方案成为FL领域的热点话题,有望实现FL的无化疗(chemo-free)治疗模式,当前更多的研究证实无化疗方案在FL患者中具有良好的疗效及安全性。

天津市肿瘤医院的王先火教授分享了一篇题为“基于不同分类方法的弥漫大B细胞淋巴瘤(DLBCL)患者PD-L1表达特征分析”的论文。研究表明,DLBCL具有多种分类方法,而由此得出的患者PD-L1特征也具有一定差异。

小结

本次CSCO会议上,「国内白血病·淋巴瘤专场」紧跟且聚焦于淋巴瘤治疗的前沿——免疫及靶向治疗,尤其是BTK抑制剂在B细胞淋巴瘤中继续取得了令人鼓舞和兴奋的疗效,另外PD-1/PD-L1抑制剂等免疫治疗也是热点研究方向。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1943068, encodeId=be241943068ca, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Oct 23 21:48:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852138, encodeId=34c81852138a5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 22 18:48:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702594, encodeId=27381e025946c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 04 04:48:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273326, encodeId=da7112e332653, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297380, encodeId=ea7f129e380b8, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539099, encodeId=daf41539099d8, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1943068, encodeId=be241943068ca, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Oct 23 21:48:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852138, encodeId=34c81852138a5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 22 18:48:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702594, encodeId=27381e025946c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 04 04:48:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273326, encodeId=da7112e332653, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297380, encodeId=ea7f129e380b8, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539099, encodeId=daf41539099d8, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
    2020-02-22 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1943068, encodeId=be241943068ca, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Oct 23 21:48:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852138, encodeId=34c81852138a5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 22 18:48:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702594, encodeId=27381e025946c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 04 04:48:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273326, encodeId=da7112e332653, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297380, encodeId=ea7f129e380b8, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539099, encodeId=daf41539099d8, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1943068, encodeId=be241943068ca, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Oct 23 21:48:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852138, encodeId=34c81852138a5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 22 18:48:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702594, encodeId=27381e025946c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 04 04:48:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273326, encodeId=da7112e332653, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297380, encodeId=ea7f129e380b8, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539099, encodeId=daf41539099d8, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1943068, encodeId=be241943068ca, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Oct 23 21:48:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852138, encodeId=34c81852138a5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 22 18:48:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702594, encodeId=27381e025946c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 04 04:48:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273326, encodeId=da7112e332653, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297380, encodeId=ea7f129e380b8, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539099, encodeId=daf41539099d8, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1943068, encodeId=be241943068ca, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Oct 23 21:48:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852138, encodeId=34c81852138a5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 22 18:48:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702594, encodeId=27381e025946c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 04 04:48:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273326, encodeId=da7112e332653, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297380, encodeId=ea7f129e380b8, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539099, encodeId=daf41539099d8, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 05 01:48:00 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
    2019-10-05 fengting7

相关资讯

日本宣布攻克白血病?真的假的?

近日,一则题为《日本宣布攻克白血病,国内媒体一片沉默》的文章出现在网络上。

NEJM:全球首例 中国科学家利用基因编辑治疗艾滋病和白血病

9月13日,中国北京大学-清华大学生命科学联合中心、首都医科大学附属北京佑安医院以及解放军总医院第五医学中心的研究人员日前在国际顶级医学杂志《The New England Journal of Medicine》(简称:NEJM)上发表了题为《CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukem

“打双靶”让癌细胞无路可逃 急性白血病耐药迎来新曙光

来自美国国立卫生研究院(NIH)和辛辛那提儿童医院医学中心的科学家们已经设计出一种潜在的方法来抵御急性髓性白血病(AML)的适应性抵抗(癌细胞逃避药物的作用)。这是一种常见的白血病,可能会导致许多其他类型的癌症。在一系列的研究中,研究者们发现了一种AML逃避活性药物的细胞途径。然后,他们设计出一种化合物,目标是对癌症发起双管齐下的攻击。在一些实验中,这种化合物阻断了导致AML的突变蛋白,同时阻止了

白血病治疗耐药怎么办?新疗法“从抗体开始 根除癌细胞

在影视剧中,白血病一度是“绝症”的代名词。其中急性白血病进展很快,若不治疗,生存期很短。急性白血病通常又可分为急性淋巴细胞白血病(ALL)和急性髓细胞白血病(AML)。急性淋巴细胞白血病(ALL)是一种起源于淋巴细胞的B系或T系细胞在骨髓内异常增生的恶性血液肿瘤,约占成人白血病的1/5,也是最常见的儿童癌症之一。

Cancer Cell:5000种药物测试,旧药改造助力白血病治疗

急性髓(细胞)性白血病(AML)是一种起源于血液干细胞的癌症,常见于成人,是最致命的白血病。即使在接受化疗和骨髓移植后,具有某些遗传特征的个体的预期寿命也不到三年。蒙特利尔大学免疫与癌症研究所(IRIC)干细胞分子遗传学研究中心的首席研究员Guy Sauvageau博士牵头,对AML展开研究,企图寻找更有效的治疗方式。5000种药物测试在发现新的治疗方法之前,Sauvageau博士和他的团队首先面

Nature:发现惊人机制:让免疫系统找到癌症干细胞

白血病干细胞能通过抑制杀伤细胞的靶分子来保护自身免受免疫细胞的攻击。这种保护机制可以被药物“欺骗”。